Special Mitigation Margin for COVID-19 Up for Debate towards FY2022 Drug Price Revision: MHLW Bureau Chief

January 15, 2021
Hiroki Hamaya, Director General, Health Insurance Bureau, MHLW For its first “off-year” re-pricing this April, the government has decided to add 0.8% to the so-called adjustment rate used in its drug price revision formula in order to soften the impact...read more